Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
Proteogenomics drives therapeutic hypothesis generation for precision oncology.

British journal of cancer

Lei JT, Zhang B.
PMID: 33767418
Br J Cancer. 2021 Jul;125(1):1-3. doi: 10.1038/s41416-021-01346-5. Epub 2021 Mar 25.

Precision oncology has largely been driven by genomic profiling, but success so far has been limited. By combining genomic and proteomic analyses of tumours, proteogenomics holds promise in providing deeper mechanistic insights and generating therapeutic hypotheses to better match...

Cite
Lei JT, Zhang B. Proteogenomics drives therapeutic hypothesis generation for precision oncology. Br J Cancer. 2021;125(1):1-3doi: 10.1038/s41416-021-01346-5.
Lei, J. T., & Zhang, B. (2021). Proteogenomics drives therapeutic hypothesis generation for precision oncology. British journal of cancer, 125(1), 1-3. https://doi.org/10.1038/s41416-021-01346-5
Lei, Jonathan T, and Zhang, Bing. "Proteogenomics drives therapeutic hypothesis generation for precision oncology." British journal of cancer vol. 125,1 (2021): 1-3. doi: https://doi.org/10.1038/s41416-021-01346-5
Lei JT, Zhang B. Proteogenomics drives therapeutic hypothesis generation for precision oncology. Br J Cancer. 2021 Jul;125(1):1-3. doi: 10.1038/s41416-021-01346-5. Epub 2021 Mar 25. PMID: 33767418; PMCID: PMC8257710.
Copy Download .nbib Format: NLM
Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer.

Cancer research

Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, Fandino D, Han A, Rehman S, Hu J, Korchina V, Doddapaneni H, Dobrolecki LE, Mitsiades N, Lewis MT, Welm AL, Li S, Lee AV, Robinson DR, Foulds CE, Ellis MJ.
PMID: 34711608
Cancer Res. 2021 Oct 28; doi: 10.1158/0008-5472.CAN-21-1256. Epub 2021 Oct 28.

Genomic analysis has recently identified multiple ESR1 gene translocations in estrogen receptor-alpha positive (ERα+) metastatic breast cancer (MBC) that encode chimeric proteins whereby the ESR1 ligand binding domain (LBD) is replaced by C-terminal sequences from many different gene partners....

Cite
Gou X, Anurag M, Lei JT, et al. Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer. Cancer Res. 2021;doi: 10.1158/0008-5472.CAN-21-1256.
Gou, X., Anurag, M., Lei, J. T., Kim, B. J., Singh, P., Seker, S., Fandino, D., Han, A., Rehman, S., Hu, J., Korchina, V., Doddapaneni, H., Dobrolecki, L. E., Mitsiades, N., Lewis, M. T., Welm, A. L., Li, S., Lee, A. V., Robinson, D. R., Foulds, C. E., & Ellis, M. J. (2021). Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer. Cancer research, . https://doi.org/10.1158/0008-5472.CAN-21-1256
Gou, Xuxu, et al. "Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer." Cancer research vol. (2021). doi: https://doi.org/10.1158/0008-5472.CAN-21-1256
Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, Fandino D, Han A, Rehman S, Hu J, Korchina V, Doddapaneni H, Dobrolecki LE, Mitsiades N, Lewis MT, Welm AL, Li S, Lee AV, Robinson DR, Foulds CE, Ellis MJ. Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer. Cancer Res. 2021 Oct 28; doi: 10.1158/0008-5472.CAN-21-1256. Epub 2021 Oct 28. PMID: 34711608.
Copy Download .nbib Format: NLM
A proteogenomic portrait of lung squamous cell carcinoma.

Cell

Satpathy S, Krug K, Jean Beltran PM, Savage SR, Petralia F, Kumar-Sinha C, Dou Y, Reva B, Kane MH, Avanessian SC, Vasaikar SV, Krek A, Lei JT, Jaehnig EJ, Omelchenko T, Geffen Y, Bergstrom EJ, Stathias V, Christianson KE, Heiman DI, Cieslik MP, Cao S, Song X, Ji J, Liu W, Li K, Wen B, Li Y, Gümüş ZH, Selvan ME, Soundararajan R, Visal TH, Raso MG, Parra ER, Babur Ö, Vats P, Anand S, Schraink T, Cornwell M, Rodrigues FM, Zhu H, Mo CK, Zhang Y, da Veiga Leprevost F, Huang C, Chinnaiyan AM, Wyczalkowski MA, Omenn GS, Newton CJ, Schurer S, Ruggles KV, Fenyö D, Jewell SD, Thiagarajan M, Mesri M, Rodriguez H, Mani SA, Udeshi ND, Getz G, Suh J, Li QK, Hostetter G, Paik PK, Dhanasekaran SM, Govindan R, Ding L, Robles AI, Clauser KR, Nesvizhskii AI, Wang P, Carr SA, Zhang B, Mani DR, Gillette MA.
PMID: 34358469
Cell. 2021 Aug 05;184(16):4348-4371.e40. doi: 10.1016/j.cell.2021.07.016.

Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a deeper exposition of LSCC biology with potential therapeutic implications. We identify NSD3 as an...

Cite
Satpathy S, Krug K, Jean Beltran PM, et al. A proteogenomic portrait of lung squamous cell carcinoma. Cell. 2021;184(16):4348-4371.e40doi: 10.1016/j.cell.2021.07.016.
Satpathy, S., Krug, K., Jean Beltran, P. M., Savage, S. R., Petralia, F., Kumar-Sinha, C., Dou, Y., Reva, B., Kane, M. H., Avanessian, S. C., Vasaikar, S. V., Krek, A., Lei, J. T., Jaehnig, E. J., Omelchenko, T., Geffen, Y., Bergstrom, E. J., Stathias, V., Christianson, K. E., Heiman, D. I., Cieslik, M. P., Cao, S., Song, X., Ji, J., Liu, W., Li, K., Wen, B., Li, Y., Gümüş, Z. H., Selvan, M. E., Soundararajan, R., Visal, T. H., Raso, M. G., Parra, E. R., Babur, �. �., Vats, P., Anand, S., Schraink, T., Cornwell, M., Rodrigues, F. M., Zhu, H., Mo, C. K., Zhang, Y., da Veiga Leprevost, F., Huang, C., Chinnaiyan, A. M., Wyczalkowski, M. A., Omenn, G. S., Newton, C. J., Schurer, S., Ruggles, K. V., Fenyö, D., Jewell, S. D., Thiagarajan, M., Mesri, M., Rodriguez, H., Mani, S. A., Udeshi, N. D., Getz, G., Suh, J., Li, Q. K., Hostetter, G., Paik, P. K., Dhanasekaran, S. M., Govindan, R., Ding, L., Robles, A. I., Clauser, K. R., Nesvizhskii, A. I., Wang, P., Carr, S. A., Zhang, B., Mani, D. R., Gillette, M. A. (2021). A proteogenomic portrait of lung squamous cell carcinoma. Cell, 184(16), 4348-4371.e40. https://doi.org/10.1016/j.cell.2021.07.016
Satpathy, Shankha, et al. "A proteogenomic portrait of lung squamous cell carcinoma." Cell vol. 184,16 (2021): 4348-4371.e40. doi: https://doi.org/10.1016/j.cell.2021.07.016
Satpathy S, Krug K, Jean Beltran PM, Savage SR, Petralia F, Kumar-Sinha C, Dou Y, Reva B, Kane MH, Avanessian SC, Vasaikar SV, Krek A, Lei JT, Jaehnig EJ, Omelchenko T, Geffen Y, Bergstrom EJ, Stathias V, Christianson KE, Heiman DI, Cieslik MP, Cao S, Song X, Ji J, Liu W, Li K, Wen B, Li Y, Gümüş ZH, Selvan ME, Soundararajan R, Visal TH, Raso MG, Parra ER, Babur Ö, Vats P, Anand S, Schraink T, Cornwell M, Rodrigues FM, Zhu H, Mo CK, Zhang Y, da Veiga Leprevost F, Huang C, Chinnaiyan AM, Wyczalkowski MA, Omenn GS, Newton CJ, Schurer S, Ruggles KV, Fenyö D, Jewell SD, Thiagarajan M, Mesri M, Rodriguez H, Mani SA, Udeshi ND, Getz G, Suh J, Li QK, Hostetter G, Paik PK, Dhanasekaran SM, Govindan R, Ding L, Robles AI, Clauser KR, Nesvizhskii AI, Wang P, Carr SA, Zhang B, Mani DR, Gillette MA. A proteogenomic portrait of lung squamous cell carcinoma. Cell. 2021 Aug 05;184(16):4348-4371.e40. doi: 10.1016/j.cell.2021.07.016. PMID: 34358469; PMCID: PMC8475722.
Copy Download .nbib Format: NLM
A proteogenomic portrait of lung squamous cell carcinoma.

Cell

Satpathy S, Krug K, Jean Beltran PM, Savage SR, Petralia F, Kumar-Sinha C, Dou Y, Reva B, Kane MH, Avanessian SC, Vasaikar SV, Krek A, Lei JT, Jaehnig EJ, Omelchenko T, Geffen Y, Bergstrom EJ, Stathias V, Christianson KE, Heiman DI, Cieslik MP, Cao S, Song X, Ji J, Liu W, Li K, Wen B, Li Y, Gümüş ZH, Selvan ME, Soundararajan R, Visal TH, Raso MG, Parra ER, Babur Ö, Vats P, Anand S, Schraink T, Cornwell M, Rodrigues FM, Zhu H, Mo CK, Zhang Y, da Veiga Leprevost F, Huang C, Chinnaiyan AM, Wyczalkowski MA, Omenn GS, Newton CJ, Schurer S, Ruggles KV, Fenyö D, Jewell SD, Thiagarajan M, Mesri M, Rodriguez H, Mani SA, Udeshi ND, Getz G, Suh J, Li QK, Hostetter G, Paik PK, Dhanasekaran SM, Govindan R, Ding L, Robles AI, Clauser KR, Nesvizhskii AI, Wang P, Carr SA, Zhang B, Mani DR, Gillette MA.
PMID: 34358469
Cell. 2021 Aug 05;184(16):4348-4371.e40. doi: 10.1016/j.cell.2021.07.016.

Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a deeper exposition of LSCC biology with potential therapeutic implications. We identify NSD3 as an...

Cite
Satpathy S, Krug K, Jean Beltran PM, et al. A proteogenomic portrait of lung squamous cell carcinoma. Cell. 2021;184(16):4348-4371.e40doi: 10.1016/j.cell.2021.07.016.
Satpathy, S., Krug, K., Jean Beltran, P. M., Savage, S. R., Petralia, F., Kumar-Sinha, C., Dou, Y., Reva, B., Kane, M. H., Avanessian, S. C., Vasaikar, S. V., Krek, A., Lei, J. T., Jaehnig, E. J., Omelchenko, T., Geffen, Y., Bergstrom, E. J., Stathias, V., Christianson, K. E., Heiman, D. I., Cieslik, M. P., Cao, S., Song, X., Ji, J., Liu, W., Li, K., Wen, B., Li, Y., Gümüş, Z. H., Selvan, M. E., Soundararajan, R., Visal, T. H., Raso, M. G., Parra, E. R., Babur, �. �., Vats, P., Anand, S., Schraink, T., Cornwell, M., Rodrigues, F. M., Zhu, H., Mo, C. K., Zhang, Y., da Veiga Leprevost, F., Huang, C., Chinnaiyan, A. M., Wyczalkowski, M. A., Omenn, G. S., Newton, C. J., Schurer, S., Ruggles, K. V., Fenyö, D., Jewell, S. D., Thiagarajan, M., Mesri, M., Rodriguez, H., Mani, S. A., Udeshi, N. D., Getz, G., Suh, J., Li, Q. K., Hostetter, G., Paik, P. K., Dhanasekaran, S. M., Govindan, R., Ding, L., Robles, A. I., Clauser, K. R., Nesvizhskii, A. I., Wang, P., Carr, S. A., Zhang, B., Mani, D. R., Gillette, M. A. (2021). A proteogenomic portrait of lung squamous cell carcinoma. Cell, 184(16), 4348-4371.e40. https://doi.org/10.1016/j.cell.2021.07.016
Satpathy, Shankha, et al. "A proteogenomic portrait of lung squamous cell carcinoma." Cell vol. 184,16 (2021): 4348-4371.e40. doi: https://doi.org/10.1016/j.cell.2021.07.016
Satpathy S, Krug K, Jean Beltran PM, Savage SR, Petralia F, Kumar-Sinha C, Dou Y, Reva B, Kane MH, Avanessian SC, Vasaikar SV, Krek A, Lei JT, Jaehnig EJ, Omelchenko T, Geffen Y, Bergstrom EJ, Stathias V, Christianson KE, Heiman DI, Cieslik MP, Cao S, Song X, Ji J, Liu W, Li K, Wen B, Li Y, Gümüş ZH, Selvan ME, Soundararajan R, Visal TH, Raso MG, Parra ER, Babur Ö, Vats P, Anand S, Schraink T, Cornwell M, Rodrigues FM, Zhu H, Mo CK, Zhang Y, da Veiga Leprevost F, Huang C, Chinnaiyan AM, Wyczalkowski MA, Omenn GS, Newton CJ, Schurer S, Ruggles KV, Fenyö D, Jewell SD, Thiagarajan M, Mesri M, Rodriguez H, Mani SA, Udeshi ND, Getz G, Suh J, Li QK, Hostetter G, Paik PK, Dhanasekaran SM, Govindan R, Ding L, Robles AI, Clauser KR, Nesvizhskii AI, Wang P, Carr SA, Zhang B, Mani DR, Gillette MA. A proteogenomic portrait of lung squamous cell carcinoma. Cell. 2021 Aug 05;184(16):4348-4371.e40. doi: 10.1016/j.cell.2021.07.016. PMID: 34358469; PMCID: PMC8475722.
Copy Download .nbib Format: NLM
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.

Cancer research

Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, Fandino D, Han A, Rehman S, Hu J, Korchina V, Doddapaneni H, Dobrolecki LE, Mitsiades N, Lewis MT, Welm AL, Li S, Lee AV, Robinson DR, Foulds CE, Ellis MJ.
PMID: 34711608
Cancer Res. 2021 Dec 15;81(24):6259-6272. doi: 10.1158/0008-5472.CAN-21-1256. Epub 2021 Oct 28.

Genomic analysis has recently identified multiple

Cite
Gou X, Anurag M, Lei JT, et al. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021;81(24):6259-6272doi: 10.1158/0008-5472.CAN-21-1256.
Gou, X., Anurag, M., Lei, J. T., Kim, B. J., Singh, P., Seker, S., Fandino, D., Han, A., Rehman, S., Hu, J., Korchina, V., Doddapaneni, H., Dobrolecki, L. E., Mitsiades, N., Lewis, M. T., Welm, A. L., Li, S., Lee, A. V., Robinson, D. R., Foulds, C. E., & Ellis, M. J. (2021). Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer research, 81(24), 6259-6272. https://doi.org/10.1158/0008-5472.CAN-21-1256
Gou, Xuxu, et al. "Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer." Cancer research vol. 81,24 (2021): 6259-6272. doi: https://doi.org/10.1158/0008-5472.CAN-21-1256
Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, Fandino D, Han A, Rehman S, Hu J, Korchina V, Doddapaneni H, Dobrolecki LE, Mitsiades N, Lewis MT, Welm AL, Li S, Lee AV, Robinson DR, Foulds CE, Ellis MJ. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021 Dec 15;81(24):6259-6272. doi: 10.1158/0008-5472.CAN-21-1256. Epub 2021 Oct 28. PMID: 34711608.
Copy Download .nbib Format: NLM
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.

Cancer research

Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, Fandino D, Han A, Rehman S, Hu J, Korchina V, Doddapaneni H, Dobrolecki LE, Mitsiades N, Lewis MT, Welm AL, Li S, Lee AV, Robinson DR, Foulds CE, Ellis MJ.
PMID: 34711608
Cancer Res. 2021 Dec 15;81(24):6259-6272. doi: 10.1158/0008-5472.CAN-21-1256. Epub 2021 Oct 28.

Genomic analysis has recently identified multiple

Cite
Gou X, Anurag M, Lei JT, et al. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021;81(24):6259-6272doi: 10.1158/0008-5472.CAN-21-1256.
Gou, X., Anurag, M., Lei, J. T., Kim, B. J., Singh, P., Seker, S., Fandino, D., Han, A., Rehman, S., Hu, J., Korchina, V., Doddapaneni, H., Dobrolecki, L. E., Mitsiades, N., Lewis, M. T., Welm, A. L., Li, S., Lee, A. V., Robinson, D. R., Foulds, C. E., & Ellis, M. J. (2021). Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer research, 81(24), 6259-6272. https://doi.org/10.1158/0008-5472.CAN-21-1256
Gou, Xuxu, et al. "Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer." Cancer research vol. 81,24 (2021): 6259-6272. doi: https://doi.org/10.1158/0008-5472.CAN-21-1256
Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, Fandino D, Han A, Rehman S, Hu J, Korchina V, Doddapaneni H, Dobrolecki LE, Mitsiades N, Lewis MT, Welm AL, Li S, Lee AV, Robinson DR, Foulds CE, Ellis MJ. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021 Dec 15;81(24):6259-6272. doi: 10.1158/0008-5472.CAN-21-1256. Epub 2021 Oct 28. PMID: 34711608.
Copy Download .nbib Format: NLM
Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases.

Current problems in cancer. Case reports

Higashiyama N, Nangia J, Shafaee MN, Chen N, Michael BL, Rimawi M, Hoyos V.
PMID: 34505091
Curr Probl Cancer Case Rep. 2020 Dec 15;2. doi: 10.1016/j.cpccr.2020.100034. Epub 2020 Oct 16.

Trastuzumab deruxtecan has been shown to have responses in heavily pretreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, the safety of this medication in patients with severe liver dysfunction and untreated or symptomatic...

Cite
Higashiyama N, Nangia J, Shafaee MN, et al. Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases. Curr Probl Cancer Case Rep. 2020;2doi: 10.1016/j.cpccr.2020.100034.
Higashiyama, N., Nangia, J., Shafaee, M. N., Chen, N., Michael, B. L., Rimawi, M., & Hoyos, V. (2020). Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases. Current problems in cancer. Case reports, 2. https://doi.org/10.1016/j.cpccr.2020.100034
Higashiyama, Nicole, et al. "Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases." Current problems in cancer. Case reports vol. 2 (2020). doi: https://doi.org/10.1016/j.cpccr.2020.100034
Higashiyama N, Nangia J, Shafaee MN, Chen N, Michael BL, Rimawi M, Hoyos V. Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases. Curr Probl Cancer Case Rep. 2020 Dec 15;2. doi: 10.1016/j.cpccr.2020.100034. Epub 2020 Oct 16. PMID: 34505091; PMCID: PMC8425325.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries